Variation in SLC19A3 and protection from microvascular damage in type 1 diabetes

Diabetes

Volumn 65, Issue 4, 2016, Pages 1022-1030

  Porta, Massimo ^a   Toppila, Iiro ^b,c   Sandholm, Niina ^b,c   Hosseini, S Mohsen ^d   Forsblom, Carol ^b,c   Hietala, Kustaa ^b,e   Borio, Lorenzo ^a   Harjutsalo, Valma ^b,c,f   Klein, Barbara E ^g   Klein, Ronald ^g   Paterson, Andrew D ^d   Groop, Per Henrik ^b,c,h  

^a UNIVERSITY OF TURIN   (Italy)

^b FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^h BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; THIAMINE TRANSPORTER SLC19A2; THIAMINE TRANSPORTER SLC19A3; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP2; UNCLASSIFIED DRUG; SLC19A3 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; END STAGE RENAL DISEASE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; CELL PROTECTION; COMPLICATION; DIABETIC ANGIOPATHY; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; META ANALYSIS (TOPIC); MIDDLE AGED;

ADULT; CASE-CONTROL STUDIES; CYTOPROTECTION; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; META-ANALYSIS AS TOPIC; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84962200859     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1247     Document Type: Article

References (40)

1. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328:1676-1685
2. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-1298
3. Hietala K, Forsblom C, Summanen P., Groop PH; Finn Diane Study Group. Heritability of proliferative diabetic retinopathy. Diabetes 2008; 57:2176-2180
4. Harjutsalo V, Katoh S, Sarti C., Tajima N, Tuomilehto J. Population-based assessment of familial clustering of diabetic nephropathy in type 1 diabetes. Diabetes 2004; 53:2449-2454
5. Sandholm N, Salem RM, McKnight A.J., et al.; DCCT/EDIC Research Group. New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 2012; 8:e1002921
6. Sandholm N, McKnight AJ, Salem R.M., et al.; FIND Consortium; FinnDiane Study Group and the GENIE Consortium. Chromosome 2q31.1 associates with ESRD in women with type 1 diabetes. J Am Soc Nephrol 2013; 24:1537-1543
7. Hosseini SM, Boright AP, Sun L, et al; DCCT/EDIC Research Group. The association of previously reported polymorphisms for microvascular complications in a meta-analysis of diabetic retinopathy. Hum Genet 2015; 134:247-257
8. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 2000; 77:S26-S30
9. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54:1615-1625
10. Singleton CK, Martin PR Molecular mechanisms of thiamine utilization. Curr Mol Med 2001; 1:197-207
11. La Selva M., Beltramo E, Pagnozzi F., et al. Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia 1996; 39:1263-1268
12. Berrone E, Beltramo E, Solimine C., Ape AU, Porta M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006; 281:9307-9313
13. Hammes HP, Du X, Edelstein D., et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9:294-299
14. Babaei-Jadidi R., Karachalias N, Ahmed N., Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 2003; 52:2110-2120
15. Thornalley PJ, Babaei-Jadidi R, Al Ali H, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007; 50:2164-2170
16. Jurgenson CT, Begley TP, Ealick SE The structural and biochemical foundations of thiamin biosynthesis. Annu Rev Biochem 2009; 78:569-603
17. Nabokina SM, Said HM Characterization of the 5'-regulatory region of the human thiamin transporter SLC19A3: in vitro and in vivo studies. Am J Physiol Gastrointest Liver Physiol 2004; 287:G822-G829
18. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002; 287:2563-2569
19. Klein R, Klein BE, Moss SE Epidemiology of proliferative diabetic retinopathy. Diabetes Care 1992; 15:1875-1891
20. Thorn LM, Forsblom C, Fagerudd J., et al.; FinnDiane Study Group. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 2005; 28:2019-2024
21. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575
22. Price AL, Patterson NJ, Plenge R.M., Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904-909
23. Willer CJ, Li Y, Abecasis GR METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010; 26:2190-2191
24. Purcell S, Cherny SS, Sham PC Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19:149-150
25. Ioannidis JP, Thomas G, Daly MJ Validating, augmenting and refining genome-wide association signals. Nat Rev Genet 2009; 10:318-329
26. Sun L, Dimitromanolakis A, Faye L.L., Paterson AD, Waggott D, Bull SB; DCCT/EDIC Research Group. BR-squared: a practical solution to the winner's curse in genome-wide scans. Hum Genet 2011; 129:545-552
27. 1(C) levels via glycemic and nonglycemic pathways. Diabetes 2010; 59:3229-3239
28. Speliotes EK, Willer CJ, Berndt S.I., et al.; MAGIC; Procardis Consortium. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010; 42:937-948
29. Willer CJ, Schmidt EM, Sengupta S, et al; Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013; 45:1274-1283
30. Ehret GB, Munroe PB, Rice K.M., et al.; International Consortium for Blood Pressure Genome-Wide Association Studies; CARDIoGRAM Consortium; CKDGen Consortium; KidneyGen Consortium; EchoGen Consortium; CHARGE-HF Consortium. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011; 478:103-109
31. Schmid H, Boucherot A, Yasuda Y., et al.; European Renal cDNA Bank (ERCB) Consortium. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 2006; 55:2993-3003
32. Eudy JD, Spiegelstein O, Barber R.C., Wlodarczyk BJ, Talbot J, Finnell RH. Identification and characterization of the human and mouse SLC19A3 gene: a novel member of the reduced folate family of micronutrient transporter genes. Mol Genet Metab 2000; 71:581-590
33. Rajgopal A, Edmondnson A, Goldman I.D., Zhao R. SLC19A3 encodes a second thiamine transporter ThTr2. Biochim Biophys Acta 2001; 1537: 175-178
34. Rindi G, Laforenza U. Thiamine intestinal transport and related issues: recent aspects. Proc Soc Exp Biol Med 2000; 224:246-255
35. Ozand PT, Gascon GG, Al Essa M, et al. Biotin-responsive basal ganglia disease: a novel entity. Brain 1998; 121:1267-1279
36. Kono S, Miyajima H, Yoshida K., Togawa A, Shirakawa K, Suzuki H. Mutations in a thiamine-transporter gene and Wernicke's-like encephalopathy. N Engl J Med 2009; 360:1792-1794
37. Alkhalaf A, Kleefstra N, Groenier K.H., et al. Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One 2012; 7:e40427
38. Alkhalaf A, Klooster A, van Oeveren W, et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010; 33:1598-1601
39. Du X, Edelstein D, Brownlee M. Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 2008; 51:1930-1932
40. Rabbani N, Thornalley PJ Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy. Diabetes Obes Metab 2011; 13:577-583